- Benign prostatic hyperplasia (BPH)
- Androgen (DHT)‑driven; not premalignant
- Incidence: 70% at age 60, 80% at age 70
- Transition/periurethral zone enlargement → urethral compression
- BPH – symptoms
- Decreased stream caliber/force, hesitancy, postvoid dribbling
- Urgency, frequency, nocturia, dysuria
- PSA may be mildly elevated (usually <10 ng/mL)
- BPH – complications UTI, bladder diverticula, hydronephrosis (rare)
- BPH – treatment
- TURP (transurethral resection)
- 5α‑reductase inhibitor: finasteride
- α‑1 blockers: terazosin, prazosin
DHT→
stromal/glandular hyperplasia→
periurethral nodules→
urethral compression
- Prostate adenocarcinoma – most common cancer in U.S. men; 2nd cancer death
- Key features
- Peripheral zone origin (vs. BPH – transitional)
- Often asymptomatic; may present with back pain (bone mets)
- DRE: induration; PSA elevation; transrectal US + biopsy
- Metastasis – obturator/pelvic lymph nodes; osteoblastic bone (lumbar spine) → ↑ alkaline phosphatase
- Grading – Gleason score (glandular differentiation); TMPRSS2‑ETS fusion in ~50%
- Treatment
- Local: prostatectomy, radiation
- Metastatic: orchiectomy, estrogens, LHRH agonists, anti‑androgens
- Prostatitis
- Acute: intraprostatic reflux of urinary pathogens
- Chronic: recurrent; nonbacterial chronic pelvic pain syndrome more common
- Findings: fever, perineal/suprapubic pain, dysuria, hematuria
- Prostate cancer metastasis to lumbar spine is osteoblastic – elevated ALP, not lytic.
- BPH involves the transitional zone; prostate cancer arises in the peripheral zone – a key anatomical distinction.